4.6 Article

Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment

期刊

PHARMACEUTICALS
卷 16, 期 11, 页码 -

出版社

MDPI
DOI: 10.3390/ph16111575

关键词

tuberculosis; pharmacokinetics; linezolid; Monte Carlo simulation; indirect response modelling; time-to-event analysis; safety; peripheral neuropathy; myelosuppression; clinical utility index

向作者/读者索取更多资源

This study analyzed therapeutic drug monitoring data of linezolid in drug-resistant tuberculosis patients and found that long-term usage of linezolid can lead to adverse events such as peripheral neuropathy, anemia, and thrombocytopenia. The study identified exposure-response relationships between linezolid exposure and these adverse events. New safety targets for individualized linezolid dosing were proposed based on the study findings.
Long-term usage of linezolid can result in adverse events such as peripheral neuropathy, anemia and thrombocytopenia. Therapeutic drug monitoring data from 75 drug-resistant tuberculosis patients treated with linezolid were analyzed using a time-to-event (TTE) approach for peripheral neuropathy and anemia and indirect response modelling for thrombocytopenia. Different time-varying linezolid pharmacokinetic exposure indices (AUC0-24h,ss, Cav, Cmax and Cmin) and patient characteristics were investigated as risk factors. A treatment duration shorter than 3 months was considered dropout and was modelled using a TTE approach. An exposure-response relationship between linezolid Cmin and both peripheral neuropathy and anemia was found. The exposure index which best described the development of thrombocytopenia was AUC0-24h. The final TTE dropout model indicated an association between linezolid Cmin and dropout. New safety targets for each adverse event were proposed which can be used for individualized linezolid dosing. According to the model predictions at 6 months of treatment, a Cmin of 0.11 mg/L and 1.4 mg/L should not be exceeded to keep the cumulative probability to develop anemia and peripheral neuropathy below 20%. The AUC0-24h should be below 111 h center dot mg/L or 270 h center dot mg/L to prevent thrombocytopenia and severe thrombocytopenia, respectively. A clinical utility assessment showed that the currently recommended dose of 600 mg once daily is safer compared to a 300 mg BID dosing strategy considering all four safety endpoints.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据